RxDoctor Payments Data

Karen Earle, MD

Internal Medicine · San Francisco, CANPI 1801833678

Payments from drug & device makers

$78,412in general payments, 2019–2025

Across 110 payments — averaging $712.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$71K
  • Sanofi-aventis U.S. LLC$6K
  • Abbott$714
  • Lilly USA, LLC$120
  • Medtronic$99
  • Insulet Corporation$77
  • plus $347 from 10 others

What the payments were for

  • Consulting fees$2,2983%
  • Speaking & faculty fees$66,80585%
  • Travel & lodging$5,4197%
  • Food & beverage$3,8315%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,412 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$144,248
Medicare patients
377
Services billed
1,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide423$519,602
JardianceEmpagliflozin254$279,503
TrulicityDulaglutide151$190,144
MounjaroTirzepatide140$182,092
JanuviaSitagliptin Phosphate37$52,791
Humalog Kwikpen U-200Insulin Lispro23$52,297
TradjentaLinagliptin44$49,020
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog41$45,031
Tresiba Flextouch U-200Insulin Degludec26$43,965
FarxigaDapagliflozin Propanediol41$43,905
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/726$36,251
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$30,571
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog48$28,592
Janumet XrSitagliptin Phos/Metformin Hcl17$22,601
Humalog Kwikpen U-100Insulin Lispro57$21,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$20$525,304445 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$120$380,484317 claims
Boehringer IngelheimJardiance, Tradjenta$21$328,523298 claims
Sanofi-aventis U.S. LLCLantus$6,042$2,51914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →